Orphan Drug Designations, Invitations to Investors Conferences, and Stock ... EIN News (press release) ... Administration (FDA) has granted orphan drug exclusivity for TREANDA all through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has advanced during or within six months of treatment with rituximab or a rituximab-containing regimen. |
